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Open access under the EThe H- and N-Ras GTPases are prominent examples of proteins, whose localizations and signalling capac-
ities are regulated by reversible palmitoylations and depalmitoylations. Recently, the novel small mole-
cule inhibitor palmostatin B has been described to inhibit Ras depalmitoylation and to revert the
phenotype of oncogenic HRasG12V transformed cells. This demonstrates that palmostatin B is a tool to
investigate the biochemical effects of the inhibition of cellular Ras depalmitoylation on Ras signalling,
which is relevant for oncology. Furthermore, it is to be expected that many proteins, of which the signal-
ling capacities depend on reversible palmitoylation, will be discovered in the near future. This stresses
the urgent need for further development of small molecule inhibitors of palmitoylation and depalmitoy-
lation in order to study their functions in cellular signalling.
 2010 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction Although the four Ras isoforms, N-Ras, H-Ras, K-Ras4A and K-1.1. Ras signalling
Ras GTPases aremolecular switches that are, among others, acti-
vated by extracellular signals via protein tyrosine kinase receptors,
such as, for example, the endothelial growth factor (EGF) receptor.
Tyrosine phosphorylation in the cytosolic domain leads to binding
of adaptor proteins, such as Grb2 and guanine exchange factor
(GEF) SOS that activates Ras GTPases. Activation results in guano-
sine-triphosphate (GTP) boundRas, which in turn activatesmultiple
downstream effectors and thus triggers changes in cellular behav-
iour.1–3 The best characterized pathway is the mitogen activated
protein kinases (MAPK) pathway, which involves Raf-1 kinase,
MEK1/2 and ERK1/2. Activated Ras can also bind and activate phos-
phoinositide-3-kinase (PI3K), which catalyses the formation of the
second messenger phosphatidylinositol-3,4,5-triphosphate.4
AnotherRas effector is phospholipaseCe (PLCe) that linksRas activa-
tion to protein kinase C (PKC) activation and calciummobilization.5
Under normal conditions, Ras activation results from speciﬁc extra-
cellular signals and is transient.However, RasGTPasesaremutation-
ally activated in several types of cancer.6,7 Mutationally activated
Ras activates downstream effectors independently from extracellu-
lar signals and thus contributes to oncogenesis. Therefore, enzymes
that regulate Ras activity gained attention as potential drug targets
for cancer therapy.8+31 50 363 7963.
lsevier OA license.Ras4B, are encoded by different genes, the Ras domains that are re-
quired for activation are nearly identical in the different isoforms.9
The differences reside in the C-terminal region referred to as hyper-
variable region (HVR), which is modiﬁed by lipid posttranslational
modiﬁcations. H-Ras is modiﬁed by two cysteine palmitoylations
and one cysteine farnesylation, whereas N-Ras and K-Ras(A) are
modiﬁedby one cysteine palmitoylation andone cysteine farnesyla-
tion. In contrast, K-Ras(B) is not palmitoylated. Reversible palmitoy-
lations ofH- andN-RasGTPases control theirmembrane attachment
and speciﬁc localization on the plasmamembrane and the Golgi.10–
13 Proper steady state localization requires a dynamic cycle of palm-
itoylationon theGolgi,which redirectsRas to theplasmamembrane,
and ubiquitous depalmitoylation to counteract spontaneous non
speciﬁcdistributionover cellular endomembranes (Fig. 1).12Disrup-
tionof this dynamic cycle results in a reductionof Ras localizationon
the Golgi and the plasma membrane, due to random redistribution
to endomembranes. This indicates that inhibitors of palmitoylation
as well as depalmitoylation alter the steady state localization of Ras
GTPases and thus Ras signalling.
1.2. Inhibition of palmitoylation
Inhibition of palmitoylation prevents membrane attachment of
Ras GTPases (Fig. 1), which results in inhibition of oncogenic Ras
signalling. The enzymes that are responsible for Ras palmitoylation
are referred to as palmitoyl acyltransferases (PATs).14 The best
know inhibitor of protein palmitoylation is 2-bromopalmitate
(2BP),12,15 which contains, however, a reactive functionality that
Figure 1. The speciﬁc subcellar localization of Ras GTPases is maintained by a dynamic cycle of ubiquitous depalmitoylation and palmitoylation on the Golgi system.
Depalmitoylation followed by palmitoylation on the Golgi redirects Ras GTPases to the plasma membrane through the secretory pathway. Inhibition of palmitoylation or
depalmitoylation provides an approach to disturb Ras localization and to inhibit local Ras activity and downstream signalling. Interfering with depalmitoylation, by
palmostatin B, leads to random distribution of Ras GTPases over endomembranes and thereby uncouples spatial regulated signalling pathways.
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small molecules without reactive functionalities that inhibit pro-
tein palmitoylation in vitro.16 These compounds inhibit plasma
membrane binding of GFP-labelled H-Ras constructs and also Ras
mediated signalling via the MAPK pathway. Development of small
molecule inhibitors of Ras palmitoylation is therefore considered
as a viable strategy to downregulate oncogenic Ras signalling.
1.3. Inhibition of depalmitoylation
In contrast to the palmitoylating enzymes, of which several en-
zyme subtypes have been characterized, only one cytosolic depalm-
itoylating enzyme has been described. The depalmitoylating
enzyme acyl protein thioesterase 1 (APT1) was initially described
as a lysophospholipase.17 It has been shown that palmitoylated pro-
teins are the preferred substrates for APT1 in vitro.18 In addition,
overexpression of this thioesterase in cellular studies demonstrated
up-regulationofdepalmitoylationofheterotrimericGproteina sub-
units and H-Ras.18 Another study demonstrated that APT1 is
involved in depalmitoylation of eNOS.19 In contrast, APT1 does
not depalmitoylate caveolin.19 This suggests that different depalm-
itoylating enzymes exist, which have not been discovered yet, or
that other, maybe non-enzymatic processes, are involved in
depalmitoylation.
Development of APT1 inhibitors gained little attention in oncol-
ogy, because it has been expected that inhibition of depalmitoyla-
tion increases the palmitoylated state of the Ras GTPase and thus
the membrane attachment, which would facilitate oncogenic sig-
nalling. However, the discovery that dynamic palmitoylation and
depalmitoylation is required to maintain proper Ras localization
indicates that inhibition of Ras depalmitoylation will disturb Ras
localization und thus Ras signalling.12,13 This was the rationale to
develop the recently described Ras depalmitoylation inhibitor pal-
mostatin B in order to downregulate oncogenic Ras signalling.15
2. Palmostatin B
2.1. Palmostatin B inhibits acyl protein thioesterase 1
Palmostatin B was developed using a knowledge based strategy,
denoted protein structure similarity clustering (PSSC).20–22 In thisstrategy proteins are assigned to clusters based on similarity in
their three dimensional structure in their ligand sensing cores.
Using this approach structural similarity was observed between
the enzymes APT1 and gastric lipase (Fig. 2). The gastric lipase
inhibitor tetrahydrolipstatin was employed to design a focused
compound collection with a b-lactone core structure (Fig. 2). This
compound collection was screened for inhibition of the enzyme
APT1 and provided the inhibitor palmostatin B as the most potent
compound (IC50 670 nM). Palmostatin B inactivates APT1 by revers-
ible covalent modiﬁcation of the enzyme active site. The enzyme is
acylated by palmostatin B through nucleophilic opening of the b-
lactone electrophile, followed by regeneration of the active enzyme
by hydrolysis of the acylated enzyme. Furthermore, a direct interac-
tion between APT1 and palmostatin B in cells was demonstrated.
Palmostatin B inhibits APT1 selectively compared with the intracel-
lular phospholipases A1, A2, Cb and D. Thus, palmostatin B is a
selective small molecule inhibitor that behaves as slowly converted
substrate and thus temporarily inhibits the APT1 enzyme activity.15
2.2. Palmostatin B inhibits Ras depalmitoylation
Normally, H- and N-Ras are mainly bound to the plasma mem-
brane and the Golgi.12 This speciﬁc distributionwas lost upon treat-
ment with palmostatin B, which is in line with the model in Figure
1.15 According to this model depalmitoylation serves as a reset
mechanism against random distribution over endomembranes.12
Consequently, inhibition of depalmitoylation blocks the transport
ofH- andN-Rasback to theGolgi. It has been shown that Palmostatin
B treatment inhibited depalmitoylation of N-Ras in cell-based stud-
ies.15 The same effect was found after siRNAmediated downregula-
tion of APT1 expression.15 The kinetics of localized cellular Ras
palmitoylation and depalmitoylation was studied using semisyn-
thetic Ras GTPases (Fig. 3A).15 The semisynthetic Ras GTPases were
obtained via a combination or organic synthesis and protein
expression. Ras GTPases with truncated C-termini were expressed
and the C-terminal peptides, with the appropriate posttranslational
modiﬁcations, were synthesized by organic chemistrymethods. The
C-terminal peptides were linked covalently to the truncated Ras
GTPases to provide functional Ras GTPases that were ﬂuorescently
labelled.23–25 These semisynthetic Ras GTPasesweremicro-injected
into livings cells and accumulation on the Golgi was measured over
Figure 2. A knowledge based approach was used for discovery of palmostatin B as APT1 inhibitor. Protein structure similarity clustering (PSSC) revealed structural similarity
between lipase and APT1 in their ligand sensing cores. The lipase inhibitor tetrahydroplipstatin was used for synthesis of a focused compound collection that was screened for
inhibition of APT1.
Figure 3. The local palmitoylation rate on the Golgi can be studied using semisynthetic Ras proteins. (A) Semisynthetic Ras GTPases are synthesized by expression of
truncated Ras GTPases that lack their C-termini. The Ras C-termini, with their appropriate posttranslational modiﬁcations, are synthesized using organic chemistry methods.
The synthetic C-termini are equipped with a maleïmide functionality that is linked covalently to the truncated Ras GTPases to provide a functional Ras GTPase. The
semisynthetic Ras GTPases are labelled with a ﬂuorophore that allows detection in living cells. (B) The semisynthetic Ras GTPases are micro-injected in living cells and the
kinetics of the ﬂuorescence increase on the Golgi is measured. Upon microinjection of the semisynthetic Ras GTPase CysFar the ﬂuorescence increase on the Golgi reﬂects the
rate of trapping of the Ras GTPase on the Golgi by palmitoylation. Upon microinjection of the semisynthetic Ras GTPase PalFar the ﬂuorescence increase on the Golgi reﬂects
the rate of trapping of the Ras GTPase on the Golgi by depalmitoylation and subsequent palmitoylation. Palmostatin B inhibits the depalmitoylation of the semisynthetic Ras
GTPase PalFar and not the palmitoylation.15
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the Golgi is a reﬂection of the palmitoylation rate of the Ras GTPase
on the Golgi, whereas the accumulation of the Ras GTPase PalFar on
the Golgi is a reﬂection of the rate of cellular depalmitoylation fol-
lowed by palmitoylation on the Golgi (Fig. 3B).12,15 Palmostatin B
inhibited the Golgi accumulation of the Ras GTPase PalFar and not
CysFar. This demonstrates that palmostatin B inhibits Ras depalmi-
toylation and not palmitoylation in living cells.
Interestingly, palmostatin B had a pronounced effect on the
compartment speciﬁc activation of H-Ras. Normally, growth factor
stimulation leads to rapid and transient activation of H-Ras on the
plasma membrane and slow but sustained activation on the
Golgi.12 Short term treatment with palmostatin B inhibited H-Ras
activation on the Golgi, whereas H-Ras activation on the plasma
membrane was not disturbed.15 Thus, palmostatin B is a tool to
uncouple Ras activity on both compartments and to study the
inﬂuence on the Ras signalling output. Finally, it was demonstrated
that palmostatin B causes phenotypic reversion of oncogenic Ras
transformed cells. Oncogenic Ras transformed MDCK-f3 cells show
a long and spindle like phenotype and grow in multiple layers with
reduced cell–cell contacts. Palmostatin B caused reversion to the
round phenotype that is characteristic for untransformed MDCK
cells.2.3. Palmostatin B selectivity
Selectivity for different enzyme subtypes is, in general, a major
concern for smallmolecule inhibitors. PalmostatinB shows selective
inhibition of APT1 compared to cellular phospholipases, such as
phospholipases A1, A2, Cb and D.15 The fact that palmostatin B be-
haves as slowly converted substrate for APT1might cause this selec-
tivity. The APT1 inhibitory potency is determined by a relatively fast
covalent inhibition rate constant as well as a relatively slow reacti-
vation rate constant. Palmostatin Bmight fail to inhibit the other en-
zymes by either a relatively slow inactivation rate or a relatively
quick reactivation rate. Nevertheless, for further efforts in drug dis-
covery, it would be important to evaluate the selectivity towards an
even broader group of enzymes. Enzymes to be included in this
group are diversemembers of the broad family of esterases. Further-
more, enzymes with related sequences such as acyl protein thioes-
terase 2 (APT2) might be inhibited by palmostatin B. Additionally,
protein structure similarity clustering (PSSC)21,22 could give indica-
tions on the selection of targets to evaluate the palmostatin B selec-
tivity. However, it should be noted that selective inhibition is
commonly found for targets with functional, structural or sequence
similarity.2.4. Selectivity in cellular Ras depalmitoylation
Two studies describe the selectivity of cellular Ras depalmitoy-
lation, which is for a signiﬁcant part mediated by APT1.15 One
study describes that no selectivity is observed in cellular depalmi-
toylation of semisynthetic Ras GTPases with structurally diverse C-
termini.26 Another study describes pulse-chase experiments,
which revealed that oncogenic H-Ras isoforms are quicker depalm-
itoylated than wild type H-Ras.27 These differences were attributed
to differences in the conformations of GTP and guanosine-diphos-
phate (GDP) bound Ras. The half life for palmitate removal from
GTP bound Ras was estimated to be less than 10 min, which is
about 20 times faster than for GDP bound Ras. This raises the idea
that cellular depalmitoylation does not depend on the structure of
the Ras C-terminus, but on the structure of Ras itself. The limited
knowledge of cellular depalmitoylating enzymes and their sub-
strate selectivity calls for further exploration of this enzyme class.2.5. Palmostatin B inhibits Ras activation on the Golgi
Interestingly, Ras signalling does not only originate from the
plasma membrane but also from other cellular compartments such
as the Golgi.28 Different downstream effects have been described
for compartment speciﬁc Ras activity and compartment speciﬁc
signalling has been demonstrated for individual Ras isoforms.28
H- and N-Ras activation on the PM is rapid and transient, whereas
activation of Ras on the Golgi is delayed and sustained.12,29
Furthermore, Ras activation on different compartments is cell-type
and signal dependent. It has been shown that Ras can be activated
on the Golgi independently from activation on the plasma mem-
brane in Jurkat cells upon T-cell receptor stimulation.30 This activa-
tion of Ras on the Golgi involves the GEF RasGRP1, which is
regulated by calcium and diacylglycerol.30 This suggests a model
in which Ras on the Golgi is activated via water soluble second
messengers and GEFs as reviewed by Quatela and Philips.31 In con-
trast to this established model, endothelial growth factor (EGF)
mediated activation of Ras on the Golgi seems to involve Ras
depalmitoylation, because short term palmostatin B treatment,
which inhibits Ras depalmitoylation, inhibits EGF mediated activa-
tion of H-Ras on the Golgi, whereas H-Ras activation on the plasma
membrane is maintained.15 This argues for a model in which Ras is
activated on the plasma membrane and is then trafﬁcked to the
Golgi by depalmitoylation in its GTP bound form. It should, how-
ever, be noted that palmostatin B might inﬂuence other signalling
mechanisms that are independent from Ras activation on the plas-
ma membrane. Which model applies for speciﬁc signals and if the
second model is correct for EGF mediated signal transduction re-
mains to be elucidated.
3. Lipid modiﬁcations in signal transduction
3.1. Ras signalling through membrane microdomains
It becomes increasingly clear that lateral segregation of Ras
GTPases into microdomains on the plasma membrane plays an
important role in Ras mediated signal transduction.32 It has been
demonstrated that both H-Ras palmitoylation sites serve distinct
roles in membrane attachment and localization to microdo-
mains.33 Furthermore, microdomains with GDP loaded H-, N- and
K-Ras are not able to activate the MAPK pathway by Raf activation,
whereas microdomains with GTP loaded Ras are capable of Raf
activation.34 These microdomains are thought to facilitate signal-
ling by concentrating the Ras GTPases to speciﬁc locations.35–37
Recently, it has been demonstrated that the formation of EGF
receptor microdomains require receptor tyrosine kinase activity
and the formation of phosphatidic acid by phospholipase D2
(PLD2).38 Inhibition of the PLD2 activity inhibited activation of
the MAPK signalling pathway. These studies show that small mol-
ecule inhibitors of lipid modifying enzymes might interfere with
multiple processes that are crucial for Ras mediated signalling.
3.2. Depalmitoylation of eNOS and Ga
Depalmitoylation is not only important for Ras mediated signal
transduction and oncology, but also for other signalling pathways
and disease models. For example, Siegel et al. demonstrated that
APT1 is involved in dentritic spine morphogenesis.39 Both palmost-
atin B (in this study denoted FD196) mediated inhibition of APT1
activity and shRNA mediated downregulation of APT1 expression
reduced dendritic spine volume. Interestingly, APT1 expression is
inhibited by microRNA 138. Ga13 palmitoylation is required for
membrane localization and Rho-dependent signalling,40 which
suggests that inhibition of depalmitoylation increases Ga13
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involvement of APT1 in spine morphogenesis links APT1 inhibition
to effects on the nervous system, which might be either beneﬁcial
or detrimental for APT1 directed drug discovery. Furthermore,
APT1 is also involved in eNOS depalmitoylation, which is linked
to vascular tone and platelet aggregation. Interestingly, APT1 cata-
lyzed depalmitoylation of eNOS is potentiated by Ca2+-calmodulin,
which is an allosteric modulator of eNOS.19 In contrast, APT1 cata-
lyzed depalmitoylation of Gas is unaffected by Ca2+-calmodulin,
which demonstrates that depalmitoylation is not only directed
by depalmitoylating enzymes, such as APT1, but also by allosteric
regulators of palmitoylated proteins.3.3. Depalmitoylation and the palmitoylome
Inhibitors of depalmitoylation, such as palmostatin B, will gain
importance in the near future, because a recently developed meth-
odology enables the identiﬁcation of all palmitoylated proteins in
cell-lysates, which is referred to as the palmitoylome.41 This meth-
odology employs the small molecule 17-octadecynoic acid that
serves as a bioorthogonal probe for labelling of palmitoylated pro-
teins in human cells.41 The power of this methodology is illustrated
by pulse-chase studies on Lck S-deacylation. This study reveals
that the broad spectrum serine hydrolase inhibitor meth-
ylarachidonylﬂuorophosphonate (MAFP) reduces Lck depalmitoy-
lation, which indicates the involvement of thioesterases like for
example APT1.42 Another example of the power of bioorthogonal
labelling of palmitoylated proteins is the discovery that S-palmi-
toylation of the interferon induced transmembrane protein 3
(IFITM3) controls its clustering in membrane compartments and
thus its antiviral activity.43 These studies demonstrate that bioor-
thogonal labelling of palmitoylated proteins in combination with
small molecule inhibitors of depalmitoylation enable the identiﬁ-
cation of proteins, whose functions are regulated by palmitoylation
and depalmitoylation. It is to be expected that many of such pro-
teins will be discovered in the near future.4. Conclusion
Palmostatin B is a small molecule that inhibits Ras depalmitoyla-
tion, which has a profound effect on Ras localization and
signalling.15 Short term inhibition prevents Ras activation on the
Golgi, which enables studies on compartment speciﬁc signalling.
Alternatively, long term inhibition of Ras depalmitoylation disturbs
its precise steady state localization and thus inhibits Ras signalling,
which is reﬂected by the phenotypic backtransformation of onco-
genic Ras transformedMDCK cells. This demonstrates that palmost-
atin B is a tools to study Ras depalmitoylation in cell-based studies.
Furthermore, it opens a new and unexpected avenue towards
further development of conceptually new therapeutic approaches
in oncology that target depalmitoylation. Moreover, it is expected
that many proteins that are regulated by reversible palmitoylation
andmanypalmitoyl transferases and thioesteraseswill be identiﬁed
in the near future, which will increase the importance of thioester-
ase inhibitors such as palmostatin B.Acknowledgement
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